Form 4: Halozyme Therapeutics SVP, CFO Nicole LaBrosse Reports Stock Transactions
SEC Form 4 Filing
Nicole LaBrosse, SVP and CFO of Halozyme Therapeutics, reports the vesting and settlement of restricted stock units and associated tax withholding.
Summary
- On February 23, 2025, Nicole LaBrosse, SVP and CFO of Halozyme Therapeutics, engaged in transactions involving the company's common stock.
- 6,688 shares were acquired through the vesting and settlement of restricted stock units (RSUs).
- 3,601 shares were disposed of to cover tax withholding obligations related to the RSU vesting at a price of $57.75.
- Following these transactions, LaBrosse directly owns 31,900 shares of common stock and 20,063 derivative securities.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices and compliance with SEC regulations, indicating stability and transparency.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine executive compensation adjustments.
Key Dates
| Date | Description |
|---|---|
| 02/23/2025 | Date of stock transactions: vesting of RSUs and tax withholding. |
| 02/24/2025 | Date of signature by Attorney-in-Fact. |
Keywords
Form 4, Halozyme Therapeutics, Nicole LaBrosse, Stock Transactions, Restricted Stock Units, Tax Withholding, Beneficial Ownership, HALO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.